Law360 (May 23, 2019, 7:54 PM EDT) -- The Federal Trade Commission said Thursday that despite an increase in the number of settlements between branded and generic-drug makers in 2016, fewer deals included the types of reverse payments that are likely to be anticompetitive.
The FTC’s Competition Bureau released its third snapshot of Hatch-Waxman settlements since the Supreme Court ruled in FTC v. Actavis that reverse payments from a branded drug manufacturer to a generic competitor to settle patent litigation can violate antitrust laws.
The report found that only one of the 232 settlements in the latest review period included a clear form of compensation to the generic maker...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!